Basic Information
Description
CD276 (Cluster of Differentiation 276) is a human protein encoded by the CD276 gene and belongs to the immunoglobulin superfamily. The transcript of B7-H3 is ubiquitously expressed in normal tissues and solid tumors, the protein is preferentially expressed only in tumor tissues. B7H3 is expressed on immune cells (such as antigen-presenting cells or macrophages) and has inhibitory roles on T cells, contributing to tumor cell immune evasion. Importantly, B7-H3 is highly overexpressed on a wide range of human solid cancers and often correlates with both negative prognosis and poor clinical outcome in patients. Recent studies have shown that B7H3 is a crucial player in tumor growth, invasion, migration, angiogenesis and metastasis beyond the immune regulatory roles. Due to its role in immune evasion, B7-H3 has become an interesting target for new immunotherapeutic treatments. B7-H3 and PD-L1 induce an inhibitory effect on T-cells and change their microenvironment to escape the anti-tumor immune response. B7-H3 and CTLA4 may act synergistically with one another, just as B7-H3 does in the PD-1 pathway.
-
Details
-
mRNA expression analysis
Strain specific analysis of B7-H3 gene expression in WT and B-hB7-H3 mice by RT-PCR. Mouse B7-h3 mRNA was detectable in splenocytes of wild-type (+/+) mice. Human B7-H3 mRNA was detectable only in H/H, but not in +/+ mice.
Strain specific analysis of B7-H3 gene expression in WT and B-hB7-H3 mice by RT-qPCR. Bone marrow were collected from WT mice and homozygous B-hB7-H3 (H/H) mice and stimulated with GM-CSF and IL4 for 7 days, and then stimulated with 10 μg/mL LPS for 24 h. The expression of hB7-H3 in B-hB7-H3 (H/H) was similar to that of mB7-H3 in the C57BL/6 (+/+) mice at mRNA level.
B-CAG-hB7-H3 MC38 binds anti-human B7-H3 antibody
Analysis of B-CAG-hB7-H3 MC38 by FACS. Flow cytometry analysis of the B-CAG-hB7-H3 MC38 was performed to assess anti-human B7-H3 Ab binding. Single live cells were gated and used for further analysis as indicated here. B-CAG-hB7-H3 MC38 binds well with enoblituzumab (in house) vs isotype control.
In vivo efficacy of anti-human B7-H3 antibody
Antitumor activity of anti-human B7-H3 antibody in B-hB7-H3 mice. (A) Anti-human B7-H3 antibody inhibited hB7-H3 MC38 tumor growth in B-hB7-H3 mice. Murine colon cancer hB7-H3 MC38 cells were subcutaneously implanted into homozygous B-hB7-H3 mice (female, 6-7 week-old, n=5). Mice were grouped according to body weight differences, and treated with anti-hB7-H3 antibody at doses and schedules in panel A. (B) Body weight changes during treatment. As shown in panel A, enoblituzumab (in house) were efficacious in controlling tumor growth in B-hB7-H3, demonstrating they provide a powerful preclinical model for in vivo evaluation of anti-human B7-H3 antibodies. Values are expressed as mean ± SEM.
Combination therapy of enoblituzumab and anti-mouse PD-1
Antitumor activity of enoblituzumab and anti-mouse PD-1 in B-hB7-H3 mice. (A) Anti-human B7-H3 antibodies combined with anti-mouse PD-1 antibody inhibited MC38 tumor growth in B-hB7-H3 mice. Murine colon cancer hB7-H3 MC38 cells were subcutaneously implanted into homozygous B-hB7-H3 mice (female, 7-8 week-old, n=6). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with enoblituzumab and anti-mouse PD-1 with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, combination of enoblituzumab (in house) and anti-mouse PD-1 shows more inhibitory effects than individual groups, demonstrating that the B-hB7-H3 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of mPD-1 antibodies and hB7-H3 antibodies. Values are expressed as mean ± SEM.
In vivo efficacy of anti-human B7-H3 antibodies
Antitumor activity of anti-human B7-H3 antibodies in B-hB7-H3 mice. (A) Anti-human B7-H3 antibodies inhibited hB7-H3 EL4 tumor growth in B-hB7-H3 mice. Murine lymphoma hB7-H3 EL4 cells were subcutaneously implanted into homozygous B-hB7-H3 mice (female, 6-7 week-old, n=6). Mice were grouped according to body weight differences, and treated with anti-hB7-H3 antibodies at doses and schedules in panel A. (B) Body weight changes during treatment. As shown in panel A, anti-human B7-H3 antibodies (in house) were efficacious in controlling tumor growth in B-hB7-H3, demonstrating they provide a powerful preclinical model for in vivo evaluation of anti-human B7-H3 antibodies. Values are expressed as mean ± SEM.
